Tarsus Pharmaceuticals, Inc. TARS 深 沪
等待开盘 07-09 09:30:00 美东时间
69.03
-1.520
-2.15%
华盛通- 最 高70.685
- 今 开70.19
- 成交量 18.06万股
- 最 低 67.84
- 昨 收 70.55
- 总市值 29.70亿
- 52周最高 85.25
- 市盈率 静 --
- 换手率 0.42%
- 52周最低 38.51
- 委 比 21.57%
- 总股本 4302.40万
- 历史最高 85.25
- 量 比 0.20
- 振 幅 4.03%
- 历史最低 10.80
- 每 手 1
- 风险率 11.02%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Tarsus Pharmaceuticals Stock Drops as Short Seller Alleges Illegal Copay Scheme
Tarsus Pharmaceuticals Inc (NASDAQ:TARS) shares are falling Wednesday. Short-seller Culper Research published a report claiming the company’s sole commercial product relies on an alleged illegal Medicare copay scheme. Here’s what you should know. Tarsus Pharmaceuticals stock is feeling bearish press...
07-02 02:13
Tarsus Pharmaceuticals Collaborates With John Cena Over Eyelid Disease Demodex Blepharitis
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced a new partnership with John Cena to raise awareness of Demodex blepharitis, a common but often overlooked eyelid disease caused by microscopic mites that live
05-14 20:41
财报速睇 | Tarsus Pharmaceuticals, Inc. 2026财年Q1营收1.62亿美元，同比增长106.9%；归母净利润亏损0.07亿美元，同比亏损缩窄72.3%
华盛资讯5月7日讯，Tarsus Pharmaceuticals, Inc.公布2026财年Q1业绩，公司Q1营收1.62亿美元，同比增长106.9%，归母净利润亏损0.07亿美元，同比亏损缩窄72.3%。
05-07 05:22
财报速睇 | Tarsus Pharmaceuticals, Inc. 2026财年Q1营收1.62亿美元，同比增长107.7%；归母净利润亏损0.07亿美元，同比亏损缩窄72.0%
华盛资讯5月7日讯，Tarsus Pharmaceuticals, Inc.公布2026财年Q1业绩，公司Q1营收1.62亿美元，同比增长107.7%，归母净利润亏损0.07亿美元，同比亏损缩窄72.0%。
05-07 05:11
Earnings Scheduled For May 6, 2026
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
美股大行评级 | 潜在涨幅85%！SoFi获机构升目标价至49美元；华尔街大行看涨AMD至400美元
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从28美元升至49美元；HC Wainwright & Co.：维持Fate Therapeutics"买入"评级，目标价从5美元升至7美元
05-05 11:40
HC Wainwright & Co. Reiterates Buy on Tarsus Pharmaceuticals, Maintains $88 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and maintains $88 price target.
05-04 18:10
Tarsus Pharma Says First Participant Dosed In Phase 2 Clinical Trial Evaluating TP-05, Investigational Oral Therapy To Prevent Lyme Disease By Killing Lyme-Infected Ticks Before Disease Transmission Occurs
– A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks before disease transmission –IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc.
03-31 20:33
美股大行评级 | 大摩将应用材料目标价升至432美元；潜在涨幅200.0%！维尔生物科技获巴克莱升目标价至30美元，维持"超配"评级
今日重点评级关注：巴克莱：维持Vir Biotechnology"超配"评级，目标价从26美元升至30美元；巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从10美元升至11美元
02-26 09:30
Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $90
Guggenheim analyst Eddie Hickman maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $87 to $90.
02-25 22:24
